RNTX — Rein Therapeutics Inc.

Summary of Aileron Therapeutics Q3 2019 Earnings Call

1. Key Financial Results and Metrics

• R&D Expenses: $4.5 million, up from $4.3 million in Q3 2018, primarily due to increased clinical development costs for ALRN-6924.
• General and Administrative Expenses: $3.4 million, compared to $3.2 million in the same period last year.
• Net Loss: $7.7 million, or $0.28 per share, compared to a net loss of $7.4 million, or $0.50 per share in Q3 2018.
• Cash Position: $24.6 million as of September 30, 2019, an increase from $20.7 million at the end of 2018, expected to fund operations into Q4 2020.

2. Strategic Updates and Business Highlights

• Leadership Changes: Aileron has strengthened its executive team, including the appointment of Dr. Vukovic as Chief Medical Officer and Kathryn Gregory as Chief Business Officer.
• R&D Focus: The company is concentrating on two clinical programs for ALRN-6924:
  • Combination Therapy: ALRN-6924 with Pfizer's IBRANCE (palbociclib) for MDM2-amplified cancers, with promising interim results showing a median progression-free survival of 4.4 months in liposarcoma patients.
  • Myelopreservation Program: Evaluating ALRN-6924 as a myelopreservation agent to mitigate chemotherapy-related toxicities in patients with p53 mutant cancers, with plans for a Phase 1b/2 trial.

3. Forward Guidance and Outlook

• Upcoming Milestones: Final data from the Phase 2a trial with palbociclib and dose optimization data for the myelopreservation program are expected in Q2 2020.
• Expansion Plans: Enrollment for two additional cohorts in the myelopreservation program is anticipated to begin in Q2 2020, contingent on resource availability.

4. Bad News, Challenges, or Points of Concern

• No Complete Responses: While the combination therapy showed promising results, there were no observed partial or complete responses in the interim analysis.
• Competitive Landscape: G1 Therapeutics has made advancements in myelopreservation, which could pose competitive pressure as Aileron seeks to establish its own regulatory pathway.
• Financial Losses: The company continues to operate at a loss, which may raise concerns about sustainability and the need for future funding.

5. Notable Q&A Insights

• Myelopreservation Study Timeline: Questions regarding timelines for FDA approaches were addressed, indicating a focus on optimizing chemotherapy delivery and potential survival benefits.
• Differentiation of ALRN-6924: The drug's unique peptide formulation offers a better safety profile compared to other MDM2 inhibitors, particularly in terms of thrombocytopenia.
• Collaboration with Pfizer: While there is excitement about the collaboration, no specific plans for further partnership disclosures were made at this time.
• Biomarker Strategy: The myelopreservation program will utilize a biomarker-driven approach to select patients, enhancing the potential for efficacy and understanding of the drug's mechanism of action.

Overall, Aileron Therapeutics is navigating a pivotal phase with promising clinical developments, though it faces challenges in competition and financial sustainability.